Eli Lilly bags FDA nod for Verzenio in early breast cancer, but a controversial diagnostic could dog its rollout
As Eli Lilly works to consolidate its internal and Loxo teams into an oncology powerhouse, the drug giant is putting high hopes on CDK 4/6 inhibitor Verzenio to help drive the portfolio into the future. Now, the drug has scored a paradigm-altering win in early breast cancer — but will a controversial companion diagnostic hamstring Lilly’s market plans?
The FDA on Wednesday approved CDK 4/6 inhibitor Verzenio in combination with physician’s-choice endocrine therapy to cut the risk of relapse in patients with high-risk HR-positive, HER2-negative breast cancer, Lilly said in a release.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,100+ biopharma pros reading Endpoints daily — and it's free.